Previous 10 | Next 10 |
2023-11-06 08:23:39 ET More on Acumen Pharmaceuticals, Halozyme Therapeutics, etc. Navigating Acumen's Alzheimer's Risk And Reward Acumen Pharmaceuticals: Novel Alzheimer's Molecule With Positive Early Data Halozyme: Intriguing Buy Prospect Despite This Week's PDUFA ...
CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...
Halozyme Therapeutics Inc. (HALO) is expected to report $0.67 for Q3 2023
Halozyme To Report Third Quarter 2023 Financial and Operating Results PR Newswire SAN DIEGO , Oct. 30, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2023 financial and operating resu...
2023-10-27 08:47:54 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The quest to uncover the next big success story is an ongoing pursuit for investors. Three companies are captivating exemplars of success for those seeking to turn a modest investment into a fi...
2023-10-19 07:49:48 ET More on Bristol-Myers, Halozyme, etc. Bristol-Myers' Mirati Takeover: Pharma Is Either Buying Crown Jewels Or A Dud Bristol-Myers: Out Of Favor (Rating Upgrade) Bristol-Myers Squibb: How Cheap Is Cheap Enough? Bristol Myers' Opdivo gets...
Positive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE® Drug Delivery Technology for Advanced or Metastatic Clear Cell Renal Cell Carcinoma PR Newswire BMS in discussions with health auth...
2023-10-18 12:46:20 ET More on Genmab Genmab Is Down To Attractive Levels Genmab A/S (GMAB) Q2 2023 Earnings Call Transcript Seagen, Genmab succeed in Phase 3 trial for cervical cancer therapy Genmab raises FY 2023 guidance on back of Darzalex sales S...
Update: Halozyme Announces Presentation of Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery at 13th Annual PODD: Partnership Opportunities in Drug Delivery Conference PR Newswire Study met primary end point and d...
Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery PR Newswire Study met primary end point and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHAN...
News, Short Squeeze, Breakout and More Instantly...
Halozyme Therapeutics Inc. Company Name:
HALO Stock Symbol:
NASDAQ Market:
Halozyme Therapeutics Inc. Website:
Halozyme to Report Second Quarter 2024 Financial and Operating Results PR Newswire SAN DIEGO , July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating re...
2024-07-22 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...